The key strengths of this study are: its inclusion of a high-risk population, the majority of whom were node-positive and grade 3; evaluation of response in a PD-L1+ population as a key secondary endpoint; and comprehensive biomarker data, including evaluation of response in a sTIL-high population, presented in the early BC setting. This evidence concerns the gene CD274 and breast cancer.